메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

[ 메디채널 김갑성 기자 ] - Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for denifanstat (ASC40) for the treatment of moderate-to-severe acne
- 김갑성 기자
- 2025-10-14 18:00
Kyoto University Engineering Ph.D. Team Realizes Achievement Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"

[ 메디채널 김갑성 기자 ] —— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 -- The 2025 Chinese Biomaterials Congress was recently held in Shaoxing, Zhejiang, gathering leading experts including academicians from the Chinese Academy of Engineering and the Chinese Academy of Sciences, together with international figures such as U.S. National Academy of Engineering member Leonard Pinchuk, UK Royal Society Fellow Molly Stevens, and Professor Kunio Ishikawa, President of the Japanese Society for Biomaterials.&
- 김갑성 기자
- 2025-10-14 17:22
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise. Q3 2025 Highlights Q3 2025 unaudited group revenue of approximately $206 million, up 53% year-over-year. FY 2025 revenue guidance increased to $800 million to $820 million[1]. Gozellix® now fully reimbursed by Centers for Medicare and Medicaid Services
- 김갑성 기자
- 2025-10-14 14:59
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting

TAIPEI, Oct. 14, 2025 -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, which is held in Berlin, Germany, from Oct 17 to 21, 2025. Abstract: 2242Title: Preclinical development of GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor, while combined with GNTbm-38 showing potent induced tumor microenvironment remodeling activity in cancer immunotherapySession Date/Tim
- 김갑성 기자
- 2025-10-14 14:26
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China

In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo. Telitacicept met the primary endpoint and all key secondary endpoints. Patients in Telitacicept groups showed significant improvement in disease activity compared to the placebo group. Approximately 71.8% of patients receiving Telitacicept 160mg achieved an ESSDAI reduction of ≥3 points at 24 w
- 김갑성 기자
- 2025-10-14 13:44
HKEX to Introduce Hang Seng Biotech Index Futures

[ 메디채널 황정호 기자 ] Hang Seng Biotech Index Futures to launch on 28 November 2025 New futures contracts offer risk management tools for one of the fastest growing sectors in Hong Kong capital markets SFC Transaction Levy Exemption will be applied for the first six months from launch HONG KONG, Oct. 14, 2025 -- Hong Kong Exchanges and Clearing Limited (HKEX) is pleased to announce today (Tuesday) plans to launch [ 메디채널 황정호 기자 ] Hang Seng Biotech Index Futures, the latest enhancement to its growing derivatives product ecosystem. The new futures contract, which commences trad
- 황정호 기자
- 2025-10-14 12:43
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

SHANGHAI, Oct. 14, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States. This marks an important clinical achievement following EVM14's Investigational New Drug (IND) approvals by both the U.S. Food and Drug Adminis
- 김갑성 기자
- 2025-10-14 12:13
제138회 중국수출입박람회, 10월 15일 광저우에서 개장

[ 메디채널 김갑성 기자 ] 광저우, 중국 2025년 10월 14일 -- 흔히 캔톤페어(Canton Fair)라고 불리는 제138회 중국수출입박람회(China Import and Export Fair)가 광저우에서 10월 15일부터 11월 4일까지 3단계로 나뉘어 진행된다. 캔톤페어는 전시장과 별도로 전 세계 바이어들이 언제 어디서든 중국 제조업체와 상담할 수 있도록 24시간 내내 온라인 운영 상태를 유지한다. 155만 제곱미터의 전시 면적에 7만 4600개의 부스가 마련되고 참가 기업이 3만 2000개를 넘을 정도로 이번 박람회는 역대 최대 규모를 자랑한다. 제138회 중국수출입박람회는 규모뿐 아니라 혁신 면에서도 기념비적인 행사이다. 사상 처음으로, '중국 첨단 기술 회사(National High-Tech Enterprise)', '전문화/고도화 중소기업(Specialized and Sophisticated SME)', '1위 제조회사(Manufacturing Single Champion)' 등 중국 정부에서 지정한 칭호를 획득한 수출 회사 중 34%에 해당하는 1만 개 이상의 기업이 캔톤페어에 참가한다. 다양하게 마련된
- 김갑성 기자
- 2025-10-14 09:28
PRC-Saltillo Expands Global Reach with Launch of Singapore Subsidiary

SINGAPORE, Oct. 14, 2025 -- PRC-Saltillo, a leading provider of AAC (Augmentative and Alternative Communication) devices and support services, is proud to announce the official launch of its wholly owned subsidiary, PRC Saltillo Singapore Pte. Ltd. As PRC-Saltillo enters its 60th year of operation, this expansion marks a new chapter in its mission to empower voices worldwide. Founded in 1966, PRC-Saltillo has been a pioneering force in the industry and one of the few AAC companies led by speech-language pathologists, ensuring clinical relevance and user-centered design.
- 김갑성 기자
- 2025-10-14 08:00
NABR Comment on IUCN Determination

WASHINGTON, Oct. 14, 2025 -- The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the "Endangered" status determination for long-tailed macaque ("LTM") monkeys (Macaca fascicularis). The latest issuance by the IUCN follows a 2023 petition filed by the National Association for Biomedical Research (NABR) challenging the IUCN status determination. NABR's petition demonstrates that reviews by Hansen et. al., which the IUCN has used as the basis for its status determinations, misrepresent existing scientific da
- 김갑성 기자
- 2025-10-14 06:55

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 18일 18시 00분